Valneva SE, a specialty vaccine company, will report its first half 2026 consolidated financial results on Thursday, August 13, 2026. The company will host a live webcast at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update. The webcast will be accessible on Valneva’s website, with an archive available after the event concludes.

The announcement follows Valneva’s standard disclosure schedule for its interim financial performance. The company focuses on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases. Its commercial business currently markets three proprietary travel vaccines, which support the advancement of its vaccine pipeline.

Valneva’s pipeline includes the only Lyme disease vaccine candidate in advanced clinical development, partnered with Pfizer, and the world’s most clinically advanced Shigella vaccine candidate. The company aims to provide first-, best-, or only-in-class vaccine solutions for unmet medical needs.

Investors and interested parties can access the live webcast via the provided link. The archive will remain accessible for those unable to attend the live session. Valneva continues to leverage its expertise across multiple vaccine modalities to address global public health threats.

Valneva SE, a specialty vaccine company, announced that shareholders approved all resolutions recommended by the Board of Directors at its Annual General Meeting held on June 25, 2026, in Lyon, France. The approvals included the 2025 financial statements, the renewal of authorizations regarding the company's share capital, and the transfer of Valneva's registered office to Lyon following the closure of its Nantes site. These decisions mark a significant step in the company's strategic realignment and operational adjustments.

Board Reappointments and Leadership Changes

Shareholders approved the reappointment of five Board members. Anne-Marie Graffin, James Sulat, and Kathrin Jansen were reappointed for one-year terms. James Connelly was reappointed for a two-year term, and Thomas Lingelbach, Chief Executive Officer of Valneva, was reappointed for a three-year term. These reappointments ensure continuity in leadership as the company advances its vaccine pipeline and commercial business.

At a Board meeting following the AGM, Dr. Gerd Zettlmeissl, an independent director, was appointed as Chair of the Board of Directors. Dr. Zettlmeissl brings over 40 years of scientific and leadership experience in the biopharmaceutical industry, having served as chair of several non-profit vaccine organizations and biotech companies over the past 15 years. He succeeds Anne-Marie Graffin, who chaired the Board for the past three years and will continue as Vice-chair.

Strategic Priorities and Future Outlook

Dr. Gerd Zettlmeissl, Chair of Valneva's Board of Directors, emphasized his commitment to the company's strategic priorities. "I am honored to be appointed chair of the Board and would like to thank Anne-Marie for her outstanding leadership during her tenure," he stated. "I look forward to working closely with my fellow board colleagues and the management team to support Valneva’s strategic priorities and long-term value creation for shareholders."

Valneva focuses on developing prophylactic vaccines for infectious diseases with unmet medical needs. The company currently markets three proprietary travel vaccines and is advancing candidates for Lyme disease, partnered with Pfizer, and Shigella. Detailed voting results from the AGM will be available on Valneva's corporate website in the coming days.